Boston Scientific Corporation (BSX) exhibits 69.0% gross margins and 9.2% return on invested capital within Health Care (Medical/Dental Instruments), balanced against a 15.8x enterprise multiple and 6.9% implied options volatility.
Sustained 69.0% gross profitability converts into 18.0% operating margin and 9.2% ROIC, outpacing sector cost of capital.
ROIC: 9.2% // GM: 69.0%YoY revenue trajectory of +19.9% paired with 5.91% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +19.9% // FCF YLD: 5.91%Altman Z-Score of 2.77 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 2.77 // F-SCORE: 8/9Trading at 22.0x trailing P/E (18.5x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 22.0x // EV/EBITDA: 15.8xOptions market prices a ±6.9% implied move with a 0.86 put/call ratio around $42.00 max pain.
IMPL MOVE: ±6.9% // P/C: 0.86Elevated industry capital intensity and customer concentration in Medical/Dental Instruments require continuous execution to defend 14.0% net margins.
NET MARGIN: 14.0% // D/E: 0.36x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for BSX & activate live FRED threshold breach alerts.